Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications

Advanced Drug Delivery Reviews

Volumn 54, Issue 4, 2002, Pages 547-570

  Wang, Yu Sen ^a   Youngster, Stephen ^a   Grace, Michael ^a   Bausch, James ^a   Bordens, Ronald ^a   Wyss, Daniel F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Interferon alfa 2b; Intron A; NMR; PEG Intron; Pegylated positional isomer; Protein polymer conjugate

Indexed keywords

INTERFERONS; ISOMERS; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; PROTEINS;

ANTI-TUMOR ACTIVITY;

BIOMEDICAL ENGINEERING;

ALPHA2 INTERFERON; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEGINTERFERON ALPHA2B; REBETRON; RECOMBINANT ALPHA2B INTERFERON;

CIRCULAR DICHROISM; CLINICAL TRIAL; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; HEPATITIS C; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

EID: 0037124398     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00027-3     Document Type: Article

References (62)

1. Controlled-release, pegylation, liposomal formulations: New mechanisms in the delivery of injectable drugs
2. Pegylated liposomal adriamycin: A review of current and future applications
3. Colloidal systems for tumor targeting
4. Polyethylene glycol-conjugated pharmaceutical proteins
5. Virus interference. I. The interferon
6. th anniversary of the discovery of interferons
7. How cells respond to interferons
8. 2b
9. The scientific challenge of hepatitis C
10. Pathogenesis, natural history, treatment, and prevention of hepatitis C
11. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
12. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
13. Pegylated interferon-α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data
14. Improvements in protein PEGylation: Pegylated interferons for treatment of hepatitis C
15. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C
16. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
17. Efficacy and safety of pegylated (40-kd) interferon α-2a compared with interferon α-2a in noncirrhotic patients with chronic hepatitis C
18. Pegylated interferon alfa-2a (PEGASYS™) and ribavirin combination therapy for chronic hepatitis C: A phase II open-label study
19. Identification of the major positional isomer of pegylated interferon alpha-2b
20. Treatment strategies for chronic hepatitis C: Update since the 1997 National Institutes of Health consensus development conference
21. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial
22. A randomized, double-blind, placebo-controlled trial
23. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials
24. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: Effects of dose and duration
25. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
26. RNA virus error catastrophe: Direct molecular test by using ribavirin
27. Hepatitis C: Current and future treatment
28. Humans as the world's greatest evolutionary force
29. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa
30. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-α therapy
31. The uses and properties of PEG-linked proteins
32. Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation
33. Biomedical and biotechnological applications of PEG- and PM-modified proteins
34. Introduction to chemistry and biological applications of poly(ethylene) glycol
35. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice
36. Use of flexible polymers as probes of glomerular pore size
37. 2b revealed by X-ray crystallography
38. The three-dimensional high resolution structure of human interferon α-2a determined by heteronuclear NMR spectroscopy in solution
39. Objective antiviral assay of the interferons by computer assisted data collection and analysis
40. Simultaneous analysis of families of sigmoidal curves: Application to bioassay, radioligand assay, and physiological dose-response curves
41. Effects of several species of human leukocyte interferon on cytotoxic activity of NK cells and monocytes
42. Effects of recombinant and hybrid recombinant human leukocyte interferons on cytotoxic activity of natural killer cells
43. Lymphokine-activated killer cells, natural killer cells and cytokines
44. Cytokine-induced differentiation of precursor mouse CD8+ cells into cytotoxic CD8+ cells secreting Th1 or Th2 cytokines
45. Regulation of the expression of class I MHC genes
46. Alpha-Interferon-induced transcription of HLA and metallothionein genes containing homologous upstream sequences
47. Immunoregulatory properties of ISG15, an interferon-induced cytokine
48. Positional isomers of monopegylated interferon α-2a: Isolation, characterization, and biological activity
49. Rational design of a potent, long-lasting form of Interferon: A 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C
50. Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor
51. Mutational and structural analysis of the binding interface between type I interferons and their receptor Ifnar2
52. New structural and functional aspects of the type I interferon-receptor interaction revealed by comprehensive mutational analysis of the binding interface
53. Structural, functional and evolutionary implications of the three-dimensional crystal structure of murine interferon-β
54. α and β interferons and their receptor and their friends and relations
55. Functionally important conserved amino-acids in interferon-alpha 2 identified with analogues produced from synthetic genes
56. Initial and innate responses to viral infections - Pattern setting in immunity or disease
57. Interferon-induced antiviral actions and their regulation
58. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
59. Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C
60. Assessment of optimal dosing frequency of pegylated interferon alfa-2b (PegIntron) in chronic hepatitis C
61. Pegylated interferon (PEG-Intron) for chronic hepatitis C